OPDP’s First Untitled Letter of 2018 Hits Opioid Manufacturer’s Exhibit Booth for Minimizing Risks

Oops! Subscribers must be logged in to access this content.

Not A Thompson FDA Subscriber?

Unlock access to the benefits below with a no-cost, risk-free trial of the FDA Compliance Expert Suite.

Subscription Benefits

Start Your Free Trial

By signing up for a tour of the Thompson FDA Compliance Expert Suite, you are also registering to receive email offers and product updates from us. Simply click unsubscribe at the bottom of any email if you would like to discontinue delivery.

OPDP’s First Untitled Letter of 2018 Hits Opioid Manufacturer’s Exhibit Booth for Minimizing Risks

J.W. Schomisch

February 22, 2018 at 07:20 AM EST

The CDER Office of Prescription Drug Promotion (OPDP) sent a Feb. 9 Untitled Letter to Collegium Pharmaceutical, Inc., in Canton, Mass., alleging an exhibit booth for its Xtampza ER (oxycodone) extended-release capsules for oral use failed to include information about serious risks of the product. The booth was displayed at the American Society Health-System Pharmacists (ASHP... Read More

My Research Folders

You are not Logged in yet, Please login to see Your research folders.

Oops! Subscribers must be logged in to access this content.

Not A Thompson FDA Subscriber?

Unlock access to the benefits below with a no-cost, risk-free trial of the FDA Compliance Expert Suite.

Subscription Benefits

Start Your Free Trial

OPDP’s First Untitled Letter of 2018 Hits Opioid Manufacturer’s Exhibit Booth for Minimizing Risks

My Research Folders

THOMPSON FDA

COMPLIANCE EXPERT

RESOURCES

HELP

CONTACT